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1 The mouse corticotroph tumour cell line AtT-20 is a useful model to investigate the physiological
role of native somatostatin (SRIF, Somatotropin release inhibitory factor) receptor subtypes (sst1 –
sst5). The objective of this study was to characterise the pharmacological features and the functional
effects of SRIF receptors expressed by AtT-20 cells using radioligand binding and cAMP
accumulation.
2 [125I]LTT-SRIF-28, [125I]CGP 23996, [125I]Tyr10-cortistatin-14 and [125I]Tyr3-octreotide labelled
SRIF receptor binding sites with high affinity and in a saturable manner (Bmax¼ 315, 274, 239 and
206 fmolmg1, respectively). [125I]LTT-SRIF-28 labels significantly more sites than [125I]Tyr10 -
cortistatin-14 and [125I]Tyr3 -octreotide as seen previously in cells expressing pure populations of sst2
or sst5 receptors.
3 SRIF analogues displaced the binding of the four radioligands. sst2/5 receptor-selective ligands
showed much higher affinity than sst1/3/4 receptor-selective ligands. The binding profile of [
125I]Tyr3-
octreotide was different from that of [125I]LTT-SRIF-28, [125I]CGP 23996 and [125I]Tyr10-cortistatin-
14. The sst5/1 receptor-selective ligand L-817,818 identified two binding sites, one with subnanomolar
affinity (sst5 receptors) and one with micromolar affinity (sst2 receptors); however, the proportions
were different: 70 – 80% high affinity with [125I]LTT-SRIF-28, [125I]CGP 23996, [125I]Tyr10-cortistatin-
14, but only 20% with [125I]Tyr3-octreotide.
4 SRIF analogues inhibited the forskolin-stimulated cAMP levels depending on concentration. sst2/5
receptor-selective ligands were highly potent, whereas sst1/3/4 receptor-selective ligands had no
significant effects. The sst2 receptor antagonist D-Tyr
8-CYN 154806 competitively antagonised the
effects of SRIF-14 and sst2 receptor-preferring agonists, but not those of L-817,818.
5 The complex binding properties of SRIF receptor analogues indicate that sst2 and sst5 receptors
are the predominant SRIF receptors expressed on AtT-20 cell membranes with no or only negligible
presence of sst1, sst3 and sst4 receptors. In the functional studies using cAMP accumulation, only
sst2 and sst5 receptors appear to play a role. However, the ‘predominant’ receptor appears to be
the sst2 receptor, although sst5 receptors can also mediate the effect, when the ligand is not able to
activate sst2 receptors. This clearly adds flexibility to SRIF-mediated functional effects and suggests
that the physiological role of SRIF and its analogues may be mediated preferentially via one subtype
over another.
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Introduction
Somatostatin (SRIF; somatotropin release inhibitory factor) is
known to be a potent regulator of endocrine secretion
(Hannon et al., 2002a). In particular, in the anterior pituitary,
SRIF acts as a neurohormone, secreted from neurones into the
blood, and inhibiting the secretion of growth hormone (GH),
adrenocorticotropin (ACTH) as well as other pituitary
hormones. Biological actions of SRIF are exerted through
the activation of multiple heptahelical, G-protein-linked SRIF
receptor subtypes (sst1 – sst5) which are generally coupled to an
inhibition of cAMP levels (Patel, 1999). SRIF receptors have a
broad and overlapping tissue distribution; in particular, in the
rat pituitary, sst2 and sst5 receptors are the principal subtype
expressed (Mezey et al., 1998). To date, although numerous
studies have explored the SRIF receptor function when
expressed in transfected systems, assigning a pharmacological
and functional profile to an individual native SRIF receptor
remains difficult. This is due to the limited availability of
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